(Q73253198)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9113090%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Immunomodulation and enhancement of antitumor activity by co-administration of 1,3-bis(2-chloroethyl)-1-nitrosourea and thymidine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9113090%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

W J Poo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9113090%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

X Guo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9113090%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

B Haslund

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9113090%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

D E Mozdziesz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9113090%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

language of work or name

English

0 references

publication date

1 March 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9113090%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

published in

Biochemical Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9113090%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9113090%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9113090%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

705-713

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9113090%20AND%20SRC:MED&resulttype=core&format=json

The nitrosoureas and pulmonary toxicity

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

Thymidine enhancement of methotrexate and 5-fluorouracil toxicity in cultured human colon carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

Specific protection against the cytotoxicity of a new class of nitrosoureas by pyrimidine deoxyribonucleosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

Recognition of autoantigens by patients with melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

Eradication of a disseminated mouse lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea is immunologically mediated and accompanied by de novo generation of anti-tumor cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

High-dose chemotherapy without autologous bone marrow transplantation in melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

Deoxyriboside Control and Synchronization of Mitosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

A model of cell cycle control: Effects of thymidine on synchronous cell cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

7 January 2021

An overview of thymidine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

Effect of high-dose thymidine infusions in patients with mycosis fungoides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

Antibodies to normal human melanocytes in vitiligo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

Vitiligo in patients with metastatic melanoma: a good prognostic sign

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

Prognostic significance of hypopigmentation in malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

A phase I pilot study of BCNU plus thymidine in patients with refractory cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2896%2900905-7

10.1016/S0006-2952(96)00905-7

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9113090%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference